Press Releases
April 8, 2024
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Additional Formats
April 3, 2024
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Additional Formats
March 21, 2024
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Additional Formats
March 18, 2024
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Additional Formats
March 11, 2024
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
Additional Formats
March 4, 2024
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
Additional Formats
February 27, 2024
CytomX Therapeutics to Present at Upcoming March Investor Conferences
Additional Formats
January 24, 2024
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
Additional Formats
January 12, 2024
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
Additional Formats
January 4, 2024
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
Additional Formats